ERBB2 and neoplasm: Breast cancer therapies are driven by tumour biology with four main intrinsic molecular subtypes of breast cancer that show substantial differences in phenotype, prognosis, treatment response, and survival [1,2,3,4]: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and triple negative (TN) [5,6].